Peter R. Galle, MD | Authors


Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC

February 04, 2020

Peter R. Galle, MD, discusses the findings that came from the phase III IMbrave 150 clinical trial, which evaluated the combination of atezolizumab plus bevacizumab versus the standard of care, sorafenib, as frontline treatment of patients with unresectable hepatocellular carcinoma.